SHARP: What the Liver Cancer Trial Found

The first drug that worked at all

Before 2008, advanced liver cancer had no drug treatment that had ever been shown to extend life. Chemotherapy had been tried for years without success. SHARP broke that run.

Its importance is about the deadlock it ended, not the size of what it delivered. Those are different things, and conflating them is how trial reporting goes wrong.

Two main measures, and only one of them worked

SHARP set two primary outcomes: how long people lived, and how long it took for their symptoms to get worse.

Survival improved. Median overall survival was 10.7 months with sorafenib and 7.9 months with placebo, a gain of about 2.8 months. The hazard ratio for death was 0.69 (95% CI 0.55 to 0.87; p<0.001) — roughly a 31% lower risk of dying at any moment.

Time to symptoms worsening did not improve. It was 4.1 months with sorafenib and 4.9 months with placebo (p=0.77). No benefit at all on that measure.

Scans told a better story. Median time until the cancer visibly grew was 5.5 months against 2.8 months (p<0.001).

Who was enrolled

602 people with advanced hepatocellular carcinoma took part. Their tumors could not be removed by surgery, and none had received drug treatment for the cancer before.

Everyone had well-preserved liver function, graded Child-Pugh A. This matters more in liver cancer than in most cancers, because the liver itself is usually already damaged, and that damage often decides how long someone lives.

Sorafenib was taken as a 400 mg tablet twice a day. The comparison was a placebo. That was a fixed trial amount from 2007. Anyone on sorafenib now follows their own prescription.

That was the protocol amount in 2007. Anyone taking sorafenib today should follow the prescription written for them.

Side effects, and stopping early

Diarrhea, weight loss, hand-foot skin reaction and low blood phosphate were all more common with sorafenib. Most were mild to moderate, but hand-foot reaction in particular can make walking and gripping painful.

The trial was stopped at the second planned interim analysis, after 321 deaths, because the survival difference was clear.

What this study cannot tell you

• The gain was under three months on the median, and one of the two main measures showed nothing.
• Only people with Child-Pugh A liver function were studied. That leaves out many people living with liver cancer.
• Sorafenib has since been overtaken. Combination treatments have produced better results in later trials.
• It cannot say who benefits. There is no test here that separates responders from non-responders.

Questions about drug treatment for liver cancer

• What is my Child-Pugh grade, and how does it shape my options?
• Are newer first-line combinations available to me?
• What would we do about hand-foot skin reaction if it starts?
• How would we judge whether a drug is worth continuing?

Sources

This article was written from the sources below, which were checked on the source-check date shown above.

• NEJM: Sorafenib in Advanced Hepatocellular Carcinoma (SHARP) (primary)
• Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial (secondary)
• NCI: Sorafenib Tosylate (official)

How this article was prepared

Prepared by Cancer Explained's AI-assisted editorial system and checked against the sources listed below. This article has not been reviewed by a healthcare professional unless a named reviewer is specifically shown.

Cancer Explained is published by the National Cancer Information Foundation as a nonprofit-oriented public-interest education project. It is not a diagnostic service, does not recommend treatments, and is not for emergencies.

Found an error, a broken source link, outdated information, or wording that feels insensitive? Report it here — we log and act on material corrections.